A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant

Pharmaceutical Statistics

Volumn 6, Issue 1, 2007, Pages 9-22

  Mallinckrodt, Craig ^a   Chuang Stein, Christy ^b   McSorley, Paul ^c   Schwartz, Jeffrey ^b   Archibald, Donald G ^d   Perahia, David G ^a   Detke, J ^a,e,f,g   Alphs, Larry ^b  

^a ELI LILLY AND COMPANY   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MCLEAN HOSPITAL   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Maintenance of effect; Trial design

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ADULT; ARTICLE; CASE STUDY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE;

ANTIDEPRESSIVE AGENTS; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EUROPE; HUMANS; NORTH AMERICA; RECURRENCE; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947405286     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.234     Document Type: Article

References (14)

1. World Health Organization. Pharmacotherapy of depressive disorders. A consensus statement. WHO Mental Health Collaborating Centres. Journal of Affective Disorders 1989; 17:197-198.
2. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry 1998; 55:1128-1132.
3. Thase ME, Sullivan LR. Relapse and recurrence of depression. A practical approach for prevention. CNS Drugs 1995; 4:261-277.
4. Storosum JG, van Zwieten BJ, Vermeulen HD, Wohlfarth T, van den Brink W. Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. European Psychiatry 2001; 16:327-335.
5. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression (CPMP adopted April 2002). CPMP/EWP/518/97. Accessed web site October 10, 2005: http://www.emea.eu.int/htms/human/ ewp/ewpfin.htm
6. Gelenberg AJ. Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RM, Keitner GI, Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnow B, Rothbaum B, Munsaka M, Banks P, Borian FE, Keller MB. Randomized placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry 2003; 54:806-817.
7. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, La Vange L, Harrison W. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. Journal of the American Medical Assocciation 1998; 280:1665-1672.
8. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ. Duloxetine in the prevention of relapse of major depressive disorder: a double-blind, placebo-controlled study. British Journal of psychiatry 2006; 188:346-353.
9. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychotherapy & Psychosomatics 2002; 71:190-194.
10. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. Psychotherapy & Psychosomatics 2002; 71:195-199.
11. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001; 178:234-241.
12. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20mg citalopram, 40mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 1993; 8:181-188.
13. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. Journal of Clinical Psychiatry 2004; 65:44-49.
14. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 2004; 14:457-470.